| 000 | 00833 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250513150000.0 | ||
| 264 | 0 | _c19980806 | |
| 008 | 199808s 0 0 eng d | ||
| 022 | _a0735-7907 | ||
| 024 | 7 |
_a10.3109/07357909809115786 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPerez, E A | |
| 245 | 0 | 0 |
_aOral ondansetron. _h[electronic resource] |
| 260 |
_bCancer investigation _c1998 |
||
| 300 |
_a428 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAntiemetics _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOndansetron _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tCancer investigation _gvol. 16 _gno. 6 _gp. 428 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/07357909809115786 _zAvailable from publisher's website |
| 999 |
_c9645340 _d9645340 |
||